Reading Time: 6 minutesOver the last year ALS/MND clinical trials have taken centre stage, with more trials than ever opening for recruitment in the UK, the news of promising results from some trials and the approval of drugs by some regulatory authorities. With the year coming to an end, we thought we would roundup some recent clinical trial updates that were presented at the 33rd International Symposium on ALS/MND.
Category: News
Reading Time: 5 minutesThe top-line results of the Modifying Immune Response and OutComes in ALS (MIROCALS) clinical trial were announced on 6 December 2022 at the 33rd International Symposium
Reading Time: 6 minutesA recent paper (October 2022), published in the journal Journal of Pathology: Clinical Research suggests that evidence of MND can be seen inside people years before
Reading Time: 6 minutesOn Tuesday 4 October 2022, a new paper was published which investigated the risk of developing a neurodegenerative disease, such as MND, among former Scottish
Reading Time: 6 minutesOn 29th September 2022 AMX0035, a treatment for Motor Neurone Disease (MND) was approved by the Food and Drug Administration (FDA) in the United States.
Reading Time: 4 minutesEvery year at the European Network to Cure ALS (ENCALS) meeting, the Young Investigator award is presented to the brightest and best young scientist in
Reading Time: < 1 minuteMembers of the research recently attended the 20th European Network for the Cure of Amyotrophic Lateral Sclerosis (ENCALS) meeting in Edinburgh, Scotland, on the 1-3rd of June
Reading Time: 6 minutesThis year is set to be an exciting time for MND research, and we are especially hopeful that MND clinical trials will take centre stage
Reading Time: 4 minutesMy name is Oscar Wilkins and I am a PhD student working with Professors Pietro Fratta (recipient of a MND Association Research Fellowship) and Jernej